These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 1380588)

  • 1. Combination of nifedipine and doxazosin in essential hypertension.
    Donnelly R; Elliott HL; Meredith PA; Howie CA; Reid JL
    J Cardiovasc Pharmacol; 1992 Apr; 19(4):479-86. PubMed ID: 1380588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular pressor responses in treated and untreated essential hypertension.
    Donnelly R; Elliott HL; Howie CA; Sumner DJ; Reid JL
    J Cardiovasc Pharmacol; 1990 Aug; 16(2):191-6. PubMed ID: 1697373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concentration-effect relationships and individual responses to doxazosin in essential hypertension.
    Donnelly R; Elliott HL; Meredith PA; Reid JL
    Br J Clin Pharmacol; 1989 Nov; 28(5):517-26. PubMed ID: 2531605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Doxazosin in combination with atenolol in essential hypertension: a double-blind placebo-controlled multicentre trial.
    Searle M; Dathan R; Dean S; Christensen CC; Westheim A
    Eur J Clin Pharmacol; 1990; 39(3):299-300. PubMed ID: 2147909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind and cross-over comparison of once daily doxazosin and placebo with steady-state pharmacokinetics in elderly hypertensive patients.
    Scott PJ; Hosie J; Scott MG
    Eur J Clin Pharmacol; 1988; 34(2):119-23. PubMed ID: 2968267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The antihypertensive effects of doxazosin: a clinical overview.
    Cox DA; Leader JP; Milson JA; Singleton W
    Br J Clin Pharmacol; 1986; 21 Suppl 1(Suppl 1):83S-90S. PubMed ID: 2939872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prazosin GITS vs sustained release nifedipine in patients with hypertension and abnormal lipid profile: a randomized, controlled, multicenter study. Madras Hypertension Study Group.
    Misra KP; Joglekar SJ; Mukherjee S; Nanivadekar AS
    J Assoc Physicians India; 1998; Suppl 1():30-40. PubMed ID: 11233385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The addition of doxazosin to the treatment regimen of hypertensive patients not responsive to nifedipine.
    Lindner UK; von Manteuffel GE; Stafunsky M
    Am Heart J; 1988 Dec; 116(6 Pt 2):1814-20. PubMed ID: 2904756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Doxazosin in patients with hypertension.
    Conrad KA; Fagan TC; Mackie MJ; Mayshar PV; Lee S; Souhrada JF; Falkner FC; Lazar JD
    Eur J Clin Pharmacol; 1988; 35(1):21-4. PubMed ID: 2975595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single-blind study of doxazosin in the treatment of essential hypertension when added to nonresponders to angiotensin-converting enzyme inhibitor therapy.
    Englert RG; Mauersberger H
    Am Heart J; 1988 Dec; 116(6 Pt 2):1826-32. PubMed ID: 2904758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Control of coronary heart disease risk factors with doxazosin as monotherapy and in combination therapy.
    Rosenthal J
    Am Heart J; 1988 Dec; 116(6 Pt 2):1763-6. PubMed ID: 2904747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antihypertensive effect of doxazosin in hypertensive patients: comparison with atenolol.
    Baez MA; Garg DC; Jallad NS; Weidler DJ
    Br J Clin Pharmacol; 1986; 21 Suppl 1(Suppl 1):63S-67S. PubMed ID: 2939869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacodynamics and pharmacokinetics of the combination of nifedipine and doxazosin.
    Donnelly R; Elliott HL; Meredith PA; Howie CA; Reid JL
    Eur J Clin Pharmacol; 1993; 44(3):279-82. PubMed ID: 8491245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-blind comparative study of doxazosin and prazosin when administered with beta-blockers or diuretics.
    de Planque BA
    Am Heart J; 1991 Jan; 121(1 Pt 2):304-11. PubMed ID: 1670744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind comparative study of doxazosin and prazosin in the treatment of essential hypertension.
    Fukiyama K; Omae T; Iimura O; Yoshinaga K; Yagi S; Inagaki Y; Ishii M; Kaneko Y; Yamada K; Ijichi H
    Am Heart J; 1991 Jan; 121(1 Pt 2):317-22. PubMed ID: 1824654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antihypertensive effects and pharmacokinetics of single and consecutive administration of doxazosin in patients with mild to moderate essential hypertension.
    Shionoiri H; Yasuda G; Yoshimura H; Umemura S; Miyajima E; Miyakawa T; Takagi N; Kaneko Y
    J Cardiovasc Pharmacol; 1987 Jul; 10(1):90-5. PubMed ID: 2441160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-response clarification in early drug development.
    Meredith PA; Elliott HL; Donnelly R; Reid JL
    J Hypertens Suppl; 1991 Dec; 9(6):S356-7. PubMed ID: 1840197
    [No Abstract]   [Full Text] [Related]  

  • 18. An open one-year comparison of doxazosin and prazosin for mild to moderate essential hypertension.
    Torvik D; Madsbu HP
    Am J Cardiol; 1987 May; 59(14):68G-72G. PubMed ID: 2884855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of the coadministration of carvedilol and nifedipine sustained-release in the treatment of essential hypertension.
    Juttmann JR; de Vries Robles P; Venuti RP
    J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S134-7. PubMed ID: 1378141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicenter study of doxazosin in the treatment of severe essential hypertension.
    Soltero I; Guevara J; Silva H; Velasco M
    Am Heart J; 1988 Dec; 116(6 Pt 2):1767-71. PubMed ID: 2904748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.